K-Ras Mutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive Fluoropyrimidine Therapy

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-07-4906
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Antisense Gene Therapy Using Anti-K-Ras and Antitelomerase Oligonucleotides in Colorectal Cancer

Revista Espanola de Enfermedades Digestivas
MedicineGastroenterology
2005English

Tumor Protein P53 and K-Ras Gene Mutations in Peruvian Patients With Gallbladder Cancer

Asian Pacific Journal of Cancer Prevention
2019English

Antibody Distribution and Dosimetry in Patients Receiving Radiolabelled Antibody Therapy for Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
1989English

Metastatic Colorectal Cancer First-Line Treatment With Bevacizumab: The Impact of K-Ras Mutation

OncoTargets and Therapy
OncologyPharmacology
2013English

Circulating VEGF and eNOS Variations as Predictors of Outcome in Metastatic Colorectal Cancer Patients Receiving Bevacizumab

Scientific Reports
Multidisciplinary
2017English

Biomarker Signatures Correlate With Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus

Molecular Cancer Therapeutics
Cancer ResearchOncology
2015English

Detection of Mutant K-Ras DNA in Plasma or Serum of Patients With Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
1997English

RAS Oncogene Mutations and Outcome of Therapy for Childhood Acute Lymphoblastic Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2004English

Angiogenesis Genotyping and Clinical Outcome During Regorafenib Treatment in Metastatic Colorectal Cancer Patients

Scientific Reports
Multidisciplinary
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy